Related Experiment Videos
Systemic therapy for pancreatic cancer.
Andrew H Ko1, Margaret A Tempero
1San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA, USA. andrewko@medicine.ucsf.edu
Seminars in Radiation Oncology
|September 27, 2005
Summary
Advanced pancreatic cancer treatment is evolving beyond gemcitabine monotherapy. Combination therapies, pharmacokinetic improvements, and targeted agents show promise for better patient outcomes.
Area of Science:
- Oncology
- Medical Chemistry
- Pharmacology
Background:
- Pancreatic adenocarcinoma often presents at advanced stages, necessitating systemic therapy.
- Gemcitabine monotherapy has been the standard treatment for over a decade.
- Emerging research explores combination therapies and targeted agents for improved efficacy.
Purpose of the Study:
- To review current and emerging therapeutic strategies for advanced pancreatic cancer.
- To highlight the potential benefits of combination chemotherapy and targeted molecular agents.
- To discuss the role of pharmacokinetic principles in optimizing drug delivery.
Main Methods:
- Review of recent clinical studies and therapeutic advancements in pancreatic cancer.
- Analysis of data supporting combination therapy over monotherapy.
- Exploration of molecularly targeted agents and their mechanisms.
Main Results:
- Combination therapy, including platinum agents with gemcitabine, shows potential advantages.
- Pharmacokinetic-guided drug delivery may enhance treatment benefits.
- Molecularly targeted agents are under investigation for their role in tumor maintenance.
Conclusions:
- Combination therapy integrating cytotoxic agents and targeted compounds offers significant promise.
- Advancements in understanding tumor biology are driving the development of novel treatments.
- Improved clinical outcomes for advanced pancreatic cancer patients are anticipated.